EMA/CHMP recommends four new medicines and one generic for approval

26 July 2019
ema_big

Following its July 22-25 meetings, today the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) it has recommended four novel medicines for approval.

The Committee recommended granting a conditional marketing authorization for German drug major Bayer’s (BAYN: DE) Vitrakvi (larotrectinib), the first ‘histology-independent’ treatment in the European Union for solid tumors with a neurotrophic tyrosine receptor kinase (NTRK) gene fusion. NTRK gene fusions occur very frequently in a number of rare cancers.

The CHMP granted a positive opinion for GW Pharmaceuticals’ (Nasdaq: GWPH) Epidyolex (cannabidiol) for the treatment of seizures associated with Lennox-Gastaut syndrome or Dravet syndrome, two forms of epilepsy. Epidyolex contains an actibe substance derived from cannabis and is the first to receive a positive opinion in the EU centralized procedure. The CHMP’s positive opinion is based on results from four randomised, controlled Phase III trials.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical